Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin in Locally Advanced Nasopharyngeal Carcinoma
NCT06059261Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab, endostar in nasopharyngeal carcinoma (NPC), sponsored by Chongqing University Cancer Hospital. Started Feb 2026; status: recruiting.
02
Drugs
envafolimabendostar
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06059261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06059261.